DV
Dividend Vision

ACRV — Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. Common Stock (ACRV)

Total return is -88.3% over the past 3.7 years, 193.0 points behind SPY at 104.7%. Its deepest 1-year drawdown was 57.1%.

This appears to be a single-stock holding rather than a diversified ETF, representing shares of Acrivon Therapeutics, Inc., a biopharmaceutical company. The fund structure provides direct equity exposure to the company's stock performance with no stated dividend distribution rate or expense ratio information available. This holding type appeals primarily to investors seeking concentrated exposure to a specific healthcare or biotech company rather than those pursuing broad dividend income or diversified portfolio strategies.

ACRV key facts

Asset type
Stock
Asset class
Equity
Inception date
11/15/2022
Last close
$1.95
Market cap
$74,903,024
Average volume
758082.0
Beta
1.833
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.00